-
People will be able to sign up for 2025 coverage between Oct. 15 and Dec. 7. Experts say the potential changes make it important for shoppers to study closely any coverages they expect to renew.
-
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices have not delivered on those savings.
-
For the first time, Medicare will negotiate the prices of 10 common medicines. Dr. Meena Seshamani, with the Center for Medicare at CMS, and Brian Brito, VP of pharmacy at CareMax, talk about the process.
-
The judge issued an order granting the FDA's request for a stay and noting that a trial is scheduled in November.
-
Sen. Bernie Sanders’ broad statement on U.S. drug prices doesn’t paint the full picture. Studies we examined generally found that U.S. prices were 2 to 4 times those in other countries, not 10.
-
The governor moved quickly to sign a bill that will place restrictions on pharmacy benefit managers. The House and Senate unanimously passed the measure Tuesday.
-
Twitter has been a hotbed for the insulin access movement and activism surrounding other medical conditions - helping propel concern about the prices into policy. Can it continue to win with hashtags?
-
Aduhelm was recently approved by the FDA and quickly sparked controversy over its price and questionable benefits.
-
The move comes just days before a U.S. rule was set to go into effect allowing for bulk importation of drugs from Canada. Trump promised it would lower costs and be a "game changer" for seniors.
-
Florida on Monday sent the federal government its plans for a program to import prescription medicines from Canada, aimed at lowering drug prices.